MC
CLDI icon

Meteora Capital’s Calidi Biotherapeutics CLDI Stock Holding History

Meteora Capital’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-130
Closed -$141K – 257
2024
Q1 		$141K Sell
130
-20
-13% -$32.7K 0.02% 160
2023
Q4 		$436K Sell
150
-76
-34% -$326K 0.07% 151
2023
Q3 		$1.44M Buy
+226
New +$3.66M 0.25% 102

Other funds holding CLDI

RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Meteora Capital's CLDI Position: Q2 2024 in Review

Meteora Capital sold out of Calidi Biotherapeutics (CLDI) in Q2 2024, closing a stake of 130 shares — an estimated $141K sold.

Meteora Capital first reported a position in CLDI in Q3 2023 and held it in 3 quarters. The position peaked at $1.44M in Q3 2023. 29 funds tracked by Wall St. Rank hold CLDI as of Q2 2024.

  • Meteora Capital reported no remaining Calidi Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Meteora Capital sold 130 Calidi Biotherapeutics shares in Q2 2024, an estimated $141K.
  • Meteora Capital first reported a position in Calidi Biotherapeutics in Q3 2023 and held it in 3 quarters.
  • Meteora Capital's Calidi Biotherapeutics position peaked at $1.44M in Q3 2023.
  • 29 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2024.

Based on Meteora Capital's 13F filing for Q2 2024, filed 14 Aug 2024.